Signet ring cell variant cervical mucinous adenocarcinoma

Summary

Signet ring cell variant cervical mucinous adenocarcinoma (MONDO:0003768) is a disease. A subtype of cervical mucinous adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	signet ring cell variant cervical mucinous adenocarcinoma
Mondo ID	MONDO:0003768
DOID	DOID:6101
NCIT	C40205
UMLS	C1516424
MedGen	273126
GARD	0023660
Is cancer (heuristic)	no

Also known as: cervical mucinous adenocarcinoma, signet Ring cell type · cervical mucinous adenocarcinoma, signet Ring cell variant · signet ring mucinous carcinoma

Disease family

This is a subtype of cervical mucinous adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › mucinous adenocarcinoma › cervical mucinous adenocarcinoma › signet ring cell variant cervical mucinous adenocarcinoma

Related subtypes (5): uterine ligament mucinous adenocarcinoma, intestinal variant cervical mucinous adenocarcinoma, endocervical type cervical mucinous adenocarcinoma, cervical mucinous adenocarcinoma, minimal deviation variant, cervical villoglandular adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.